Role of provocation and exercise imaging for the identification of candidates for cardiac myosin inhibitors

Read full text Summarise with VIRAT
Authors: Jonas Erzeel, Sebastiaan Dhont, Marnicq Van Es, Duhan Ulgar, Bertrand Philippe, Wilfried Müllens, Pieter Martens
Cited by: 0
References: 21

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

AIMS: Left ventricular outflow tract obstruction (LVOTO) drives symptoms and functional limitation in obstructive hypertrophic cardiomyopathy (oHCM). Some patients may only show treatment-qualifying obstruction during exercise echocardiography, yet their clinical profile and response to cardiac myosin inhibition are not well defined. This study compared the characteristics and therapeutic response of patients requiring exercise echocardiography to establish eligibility for mavacamten versus those meeting criteria at rest or during Valsalva. METHODS AND RESULTS: A single-centre retrospective cohort of 56 symptomatic oHCM patients treated with mavacamten was evaluated. LVOTO was assessed at rest, with Valsalva, and during exercise; patients were classified as 'exercise' or 'non-exercise' LVOTO based on the provocation manoeuvre eliciting a qualifying gradient (≥50 mmHg). Haemodynamic (Valsalva LVOT gradient) and symptomatic (NYHA class) response were assessed at 12 and 24 weeks. A total of 42.9% qualified for mavacamten exclusively during exercise echocardiography. Although resting and Valsalva gradients were lower by definition, these patients showed similar baseline functional limitation and exercise capacity (pVO2; 17.9 ± 7.4 vs. 16.8 ± 5.5 mL/kg/min, P = .550). By 24 weeks, most patients in both groups achieved non-obstructive gradients (

Fields of Study & Subjects

Cardiomyopathy and Myosin Studies Cardiovascular Effects of Exercise Cardiovascular Function and Risk Factors

Publication details

Journal / source
ESC Heart Failure
Volume
13
Issue
2
Publication date
3 March 2026
Language
EN